Neurodegenerative disease company Transquis has emerged from stealth with $30m in series A funding to advance research conducted at Stanford.
Tranquis Therapeutics, a US-based immuno-neurology therapy developer exploiting research from Stanford University, has raised $30m in a series A round co-led by pharmaceutical firm GlaxoSmithKline.
The round was co-led by venture capital firm Remiges Ventures and also featured Vivo Capital, Hillsborough Venture, Correlation Ventures and undisclosed other investors. GlaxoSmithKline participated through its corporate venturing arm, SR One.
Tranquis is working on treatments for neurodegenerative and ageing-related diseases triggered by dysfunction in myeloid immune cells. The approach could herald…
